The FDA proposed a rule to streamline drug establishment registration for facilities making products for the U.S. market, with an emphasis on distributed biopharma manufacturing and strengthening the drug supply chain. The proposal aims to reduce friction in registration while supporting oversight of more decentralized production models. For manufacturers and sponsors using contract and distributed networks, the proposal could change compliance planning for how sites are registered and maintained in FDA systems. It also comes as supply-chain resilience remains a central policy objective in U.S. drug regulation. Companies operating CDMOs, remote fill-finish and other distributed workflows are likely to monitor how the FDA defines covered establishments, timelines, and data requirements under the proposed framework.